Nanobiotix Shares Soar Nearly 5%, Targeting Resistance at €36.20
The French biotech company records a second session of strong gains, positioning itself at the forefront of the broad Paris index. The rebound follows a week of consolidation that had brought the share price below its short-term moving averages. The annual performance remains exceptionally high.
A Rebound Bringing the Share Closer to Its MM20 After a Week of Decline
Nanobiotix shares gained 4.73% to €32.76, among the strongest rises in the SBF 120, while the broad index only increased by 0.19%. The share is moving towards its MM20 at €33.11, still 1.06% down, while the MM50 at €33.74 remains a notch above. The RSI at 42 indicates a still neutral momentum, consistent with a rebound following a digestion phase: the value still drops 6.24% over the week despite today's rise, which mitigates this weekly decline without erasing it. The MM200 at €25.02 remains far behind, nearly 31% below the current price, reflecting the rally that started a year ago.
An Annual Performance of 622% Overshadowing Any Short-Term Reading
Over twelve months, the share shows a gain of 622%, a magnitude that puts recent volatility into the context of a very strong revaluation. Over three months, the increase remains at 18.1%, and today's rebound brings the monthly performance to over 8%. During the Q1 2026 report (June 2, 2026), the company highlighted the advancement of clinical studies on JNJ-1900 (NBTXR3) and the strengthening of the Nanoprimer platform as development focuses, while noting the risks associated with limited progress in the current standard of care for inoperable NSCLC. The identified resistance at €36.20 remains the next technical level to cross to extend the momentum.
